Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
James A KarlowskyGeorge G Zhanel

Abstract

Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin. Telavancin has a dual mechanism of antibacterial action, disrupting peptidoglycan synthesis and cell membrane function. In 2014, the Clinical and Laboratory Standards Institute (CLSI) revised the antimicrobial susceptibility testing method for telavancin, resulting in minimum inhibitory concentration (MIC) determinations that are more accurate and reproducible and demonstrate greater in vitro potency than shown with the previous testing method. The CLSI testing method changes coincided with revised telavancin MIC interpretive break point criteria for susceptibility approved by the US Food and Drug Administration for Staphylococcus aureus (≤0.12 µg/mL), Streptococcus pyogenes (≤0.12 µg/mL), Streptococcus agalactiae (≤0.12 µg/mL), Streptococcus anginosus group (≤0.06 µg/mL), and Enterococcus faecalis (vancomycin susceptible, ≤0.25 µg/mL). Telavancin is equally potent against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). It demonstrates activity against isolates of heterogeneous vancomycin-intermediate S. aureus and vancomycin-intermediate S. aureus but is poorly active against vancomycin-resistant S. aureus. It also dem...Continue Reading

References

Aug 12, 2004·The Journal of Antibiotics·Michael R LeadbetterJ Kevin Judice
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrice Courvalin
Feb 17, 2007·Expert Opinion on Investigational Drugs·Somvadee LaohavaleesonDavid P Nicolau
Feb 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dawn M SievertJeffrey C Hageman
Feb 27, 2008·Antimicrobial Agents and Chemotherapy·Francis F ArhinGregory Moeck
Jul 22, 2009·Antimicrobial Agents and Chemotherapy·Klaudia Kosowska-ShickPeter C Appelbaum
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·Rodrigo E MendesRonald N Jones
Apr 21, 2010·Antimicrobial Agents and Chemotherapy·Craig M HillJames W Janc
Mar 14, 2012·Antimicrobial Agents and Chemotherapy·Yang SongBrian J Wilkinson
Apr 5, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Yang SongBrian J Wilkinson
Aug 2, 2013·Transplant Infectious Disease : an Official Journal of the Transplantation Society·T H SwartzG Patel

❮ Previous
Next ❯

Citations

Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christian E Sandrock, Andrew F Shorr
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eric Wenzler, Keith A Rodvold
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith A Rodvold
Jun 16, 2016·Frontiers in Microbiology·Ana M Guzman PrietoRob J L Willems
May 10, 2016·Expert Opinion on Drug Metabolism & Toxicology·Liapikou Adamantia, Torres Antoni
Nov 5, 2016·Biochimica Et Biophysica Acta·Petra UttlováGabriela Seydlová
Mar 16, 2017·Expert Review of Clinical Pharmacology·Ronald G HallKenna D Payne
Apr 14, 2017·The Nurse Practitioner·Allison M BellKayla R Stover
Dec 30, 2016·Infection & chemotherapy·Eun Ju Choo, Henry F Chambers
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Kristen L BunnellKeith A Rodvold
Apr 5, 2018·Expert Review of Anti-infective Therapy·Ayesha KhanCesar A Arias
Mar 23, 2017·Antimicrobial Agents and Chemotherapy·Truc T TranKavindra V Singh
Aug 29, 2018·The Nurse Practitioner·Allison M BellKayla R Stover
Aug 26, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Allison R McMullenCarey-Ann D Burnham
Feb 13, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Leonard R DuncanRodrigo E Mendes
Sep 25, 2016·Cold Spring Harbor Perspectives in Medicine·Daina ZengJohn L Pace
Sep 11, 2019·The Journal of Antimicrobial Chemotherapy·George G ZhanelUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD
Nov 7, 2019·Drugs -- Real World Outcomes·Adam M BresslerBibiana Castaneda-Ruiz
Jun 22, 2017·Therapeutic Advances in Infectious Disease·Biswadeep DasShubham Sahni
Aug 18, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Niccolò RiccardiStefano Di Bella
Apr 16, 2021·The Journal of Antimicrobial Chemotherapy·Chieh-Hsien LuHao-Chieh Chiu
Mar 23, 2019·Microbiology Spectrum·Martin VestergaardHanne Ingmer
Jul 8, 2021·Journal of Medicinal Chemistry·Paramita SarkarJayanta Haldar
Jan 25, 2018·ACS Infectious Diseases·Mark A T BlaskovichMatthew A Cooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.